Drug Profile
VRC 01 mRNA
Alternative Names: VRC-HIVMAB01060-00-AB; VRC01; VRC01 mRNA-LNPLatest Information Update: 08 Dec 2022
Price :
$50
*
At a glance
- Originator Acuitas Therapeutics
- Developer Acuitas Therapeutics; South East Asia Research Collaboration in HIV; University of Pennsylvania
- Class Antiretrovirals; Antivirals; Monoclonal antibodies; RNA
- Mechanism of Action Gene transference; HIV antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 08 Dec 2022 No development reported - Phase-II for HIV-1 infections (Adjunctive treatment) in Thailand (IV) (Acuitas Therapeutics website, December 2022) (South East Asia Research Collaboration in HIV website, December 2022)
- 12 Feb 2022 Efficacy data from a phase-II clinical trials in HIV-1 infections presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
- 28 May 2020 No recent reports of development identified for preclinical development in HIV-1-infections(Prevention) in Canada (IV, Infusion)